Lung Cancer News and Research

Latest Lung Cancer News and Research

Achievable outcomes focus of long-term postmenopausal weight loss

Research shows that successful long-term weight loss in postmenopausal women is associated with implementation of realistic and achievable dietary changes such as reducing consumption of sugar-sweetened drinks and desserts.

30 Aug 2012

Pressure’s not off for diabetic feet

Custom-made footwear for diabetes patients must offload pressure if it is to be effective at preventing ulceration, Dutch researchers emphasize.

30 Aug 2012

New York State Department of Health issues license to Veracyte's Afirma Gene Expression Classifier

Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, and Genzyme, a Sanofi company, today announced that the New York State Department of Health has issued a license enabling Veracyte's Afirma Gene Expression Classifier to be offered to patients in the state.

30 Aug 2012

Researchers identify mechanism that explains link between trichomoniasis and prostate cancer

Researchers have identified a way in which men can develop prostate cancer after contracting trichomoniasis, a curable but often overlooked sexually transmitted disease.

30 Aug 2012

NCCN announces new guidelines for patients with pancreatic Cancer

The National Comprehensive Cancer Network (NCCN), with the support of the Pancreatic Cancer Action Network, announces the latest addition to the library of NCCN Guidelines for PatientsTM, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology.

30 Aug 2012

Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia

The U.S. Food and Drug Administration today approved Sicor Biotech's tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.

30 Aug 2012

FISH assay identifies only few lung cancer patients who could benefit from crizotinib

Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails - such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.

29 Aug 2012

Allegro Diagnostics announces results from BronchoGen genomic test trial on lung cancer

Allegro Diagnostics today announced that results from its AEGIS (Airway Epithelium Gene Expression In the Diagnosis of Lung Cancer) clinical trials, to determine the accuracy of the BronchoGen genomic test, have been accepted for an oral presentation during the late-breaking abstract session at CHEST 2012 on Tuesday, October 23, 2012 at 4:30 p.m. The abstract will also be published in a supplement of the October 2012 issue of CHEST.

28 Aug 2012

International Association for the Study of Lung Cancer receives ACCME accreditation

The International Association for the Study of Lung Cancer (IASLC) has been awarded Provisional Accreditation as a Continuing Medical Education (CME) provider by the Accreditation Council for Continuing Medical Education (ACCME).

26 Aug 2012

Statins reduce pancreatitis risk

Statins reduce the risk for pancreatitis in patients with normal or mildly elevated triglyceride levels, say the authors of a large meta-analysis.

24 Aug 2012

Vandetanib shows efficacy in thyroid cancer

The tyrosine kinase inhibitor vandetanib could significantly extend progression-free survival in patients with locally advanced or metastatic differentiated radioiodine-refractory thyroid cancer, show results of a small phase II randomized trial.

24 Aug 2012

Radiating fears over diabetes in childhood cancer survivors

People who undergo pancreatic irradiation during childhood cancer therapy are at an increased risk for developing diabetes later in life, report researchers.

24 Aug 2012

GlcNAc plays a key role in keeping cancerous monsters ‘fed’

Behaving something like ravenous monsters, tumors need plentiful supplies of cellular building blocks such as amino acids and nucleotides in order to keep growing at a rapid pace and survive under harsh conditions. How such tumors meet these burgeoning demands has not been fully understood.

24 Aug 2012